The economics of adalimumab for ulcerative colitis

被引：1
|
作者：
Xie, Feng [1 ]
机构：
[1] McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON L8N 4A6, Canada
来源：
EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH | 2015年 / 15卷 / 03期
关键词：
adalimumab; cost-effectiveness; economics; infliximab; ulcerative colitis; MAINTENANCE THERAPY; INDUCTION THERAPY; LOST RESPONSE; OPEN-LABEL; INFLIXIMAB; EFFICACY; INTOLERANCE; MODERATE; METAANALYSIS; REMISSION;
D O I：
10.1586/14737167.2015.1031113
中图分类号：
R19 [保健组织与事业（卫生事业管理）];
学科分类号：
摘要：
Ulcerative colitis is a chronic inflammatory disease, characterized by diffuse mucosal inflammation in the colon. Adalimumab, as a TNF- blocker, offers a safe and efficacious treatment option for patients with moderate to severe ulcerative colitis and refractory or intolerant to conventional medications; however, its cost-effectiveness profile has not yet been well established. Future economic evaluations should choose appropriate comparators in the context of target-reimbursement decision making and focus on cost-effectiveness over a long time horizon.
引用
收藏
页码：373 / 377
页数：5
相关论文
共 50 条
  • [21] Albumin change predicts failure in ulcerative colitis treated with adalimumab
    Ishida, Natsuki
    Takahashi, Kenichi
    Asai, Yusuke
    Miyazu, Takahiro
    Tamura, Satoshi
    Tani, Shinya
    Yamade, Mihoko
    Iwaizumi, Moriya
    Hamaya, Yasushi
    Osawa, Satoshi
    Sugimoto, Ken
    PLOS ONE, 2024, 19 (01):
  • [22] Multifocal motor neuropathy following treatment with adalimumab for ulcerative colitis
    Fionda, Laura
    Vanoli, Fiammetta
    Di Pasquale, Antonella
    Leonardi, Luca
    Morino, Stefania
    Antonini, Giovanni
    JOURNAL OF NEUROLOGY, 2018, 265 (06) : 1466 - 1468
  • [23] Ulcerative colitis - from ultrastructural to clinical outcome in adalimumab therapy
    Fratila, O. C.
    Craciun, C.
    Ilias, T.
    Tent, L.
    EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2015, 45 : 42 - 43
  • [24] Efficacy of Adalimumab as a long term maintenance therapy in ulcerative colitis
    McDermott, Edel
    Murphy, Seamus
    Keegan, Denise
    O'Donoghue, Diarmuid
    Mulcahy, Hugh
    Doherty, Glen
    JOURNAL OF CROHNS & COLITIS, 2013, 7 (02): : 150 - 153
  • [25] Bullous Pemphigoid Associated with Adalimumab Therapy in a Patient with Ulcerative Colitis
    Hoffmann, Sebastian
    Berneburg, Mark
    Schreml, Stephan
    CASE REPORTS IN DERMATOLOGY, 2018, 10 (02): : 145 - 148
  • [26] Adalimumab: A Review of Its Use in the Treatment of Patients with Ulcerative Colitis
    Burness, Celeste B.
    Keating, Gillian M.
    BIODRUGS, 2013, 27 (03) : 247 - 262
  • [27] Adalimumab: A Review of Its Use in the Treatment of Patients with Ulcerative Colitis
    Celeste B. Burness
    Gillian M. Keating
    BioDrugs, 2013, 27 : 247 - 262
  • [28] Developments in the treatment of moderate to severe ulcerative colitis: focus on adalimumab
    Freeman, Hugh J.
    THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2013, 9 : 451 - 456
  • [29] Efficacy of adalimumab in a patient with hidradenitis suppurativa and concomitant ulcerative colitis
    Contreras-Steyls, M.
    Luque, P. B.
    Flores, V.
    Herrera-Ceballos, E.
    EXPERIMENTAL DERMATOLOGY, 2019, 28 : 22 - 22
  • [30] Adalimumab for ulcerative colitis—is the glass half empty or half full?
    Alessandro Armuzzi
    Daniela Pugliese
    Nature Reviews Gastroenterology & Hepatology, 2011, 8 : 249 - 251
12345